Reimagining the pharma training experience
How behavioural science can revolutionise training in the pharma industry
9th September 2020
How behavioural science can revolutionise training in the pharma industry
9th September 2020
Identifying and stopping COVID-19 co-infections with broader diagnostics
9th September 2020
How pharma can move digitalisation from theory to commercial reality
9th September 2020
Galapagos' Walid Abi-Saab on partnering with patients to make a meaningful difference in a rare and misunderstood condition
8th September 2020
Alternative digital solutions for pharma from other regulated industries
27th August 2020
The work pharmaceutical brands have done to overcome an inherent scepticism toward them must be nurtured and built on
20th August 2020
Pharmaceutical companies and technology have a critical role to play in closing gaps seen during COVID-19
19th August 2020
An overview of current treatments and their potential drug interactions
30th July 2020
Ninety percent of patients surveyed globally reported that quality of care was as good or better than prior in-person care
21st July 2020
Gary Hughes explains why we’re witnessing a complete transformation of the clinical trial process in the wake of COVID-19
14th July 2020
Why cancer care technology must support both clinicians and patients
14th July 2020
The value of pre-existing collaboration in COVID-19 clinical trials
8th July 2020
David Peacock, MSD UK’s managing director, shares his thoughts on why companies should enter the Patient Partnership Index
2nd July 2020
A look at some of pharma's approaches to addressing the potentially deadly hyperinflammation seen in some patients with COVID-19
25th June 2020